FDA Regulation of Prescription Drugs.

Over the past 5 years, the FDA has approved 182 new drugs. This overview explains the FDA’s drug-approval process, including its approach to benefit–risk assessment, drug labeling, risk evaluation and mitigation strategies, and postmarketing surveillance.

[1]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[2]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[3]  Harlan M. Krumholz,et al.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. , 2014, JAMA.

[4]  H. Imaoka,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[5]  Hylton V. Joffe,et al.  FDA Approval of Flibanserin--Treating Hypoactive Sexual Desire Disorder. , 2016, The New England journal of medicine.

[6]  G. D. Dal Pan,et al.  Regulatory Innovation in Postmarketing Risk Assessment and Management , 2012, Clinical pharmacology and therapeutics.

[7]  Khaled Bouri,et al.  Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. , 2014, JAMA.

[8]  S. Anderson,et al.  The FDA's sentinel initiative—A comprehensive approach to medical product surveillance , 2016, Clinical pharmacology and therapeutics.

[9]  Marsha E Reichman,et al.  Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.

[10]  Navjot Singh,et al.  FDA advisory committee meeting outcomes , 2012, Nature reviews. Drug discovery.

[11]  F. J. Sasinowski,et al.  Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs: Update, July 2010 to June 2014 , 2015, Therapeutic innovation & regulatory science.

[12]  F. J. Sasinowski,et al.  Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs , 2012 .